▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4158 by analyst upside · 2026-11-13
ARDT
Ardent Health, Inc.
Healthcare · Market Cap $2B · P/E 17.2x
ANALYST PRICE TARGET
-9.7%
implied upside to consensus target
Current Price $17.68
Consensus Target $15.96
Bull Target $21.0
Bear Target $12.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
5
Sell
0
52-Week Low $7.71
52-Week High $18.57
YTD Return +104.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 17.2x
Forward P/E 13.0x
EPS (TTM) $1.03
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $6.5B
Profit Margin 2.3%
52-WEEK RANGE
52-Week Low $7.71
52-Week High $18.57
Current Price $17.68
Bear Target $12.0
Bull Target $21.0
● Now $17.68 ● Target $15.96
TRADING DATA
Avg Volume 535K
YTD Return +104.6%
Analyst Count 12
Consensus Buy
Upside to Target -9.7%
Last Updated 2026-11-13

ANALYST SUMMARY

Ardent Health, Inc. (ARDT) is currently trading at $17.68 with a Wall Street consensus price target of $15.96, which is 9.7% below the current price over the next 12 months. 12 analysts currently cover ARDT, with a consensus rating of Buy - 58% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $21.0, while the most cautious has a target of $12.0.

ARDT operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 104.6% year-to-date and is currently trading near the upper end of its 52-week range of $7.71 – $18.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MD -4.2%
Pediatrix Medical Group, Inc.
$2B · P/E 17.2x · Hold
ADUS +13.9%
Addus HomeCare Corporation
$2B · P/E 20.6x · Buy
AVAH +23.4%
Aveanna Healthcare Holdings Inc.
$3B · P/E 9.7x · Buy
LKFT -10.1%
Lakefront Biotherapeutics NV
$2B · P/E 3.2x · Underperform
AUPH +12.8%
Aurinia Pharmaceuticals Inc.
$2B · P/E 7.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ARDT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BMO Capital ● Initiated
Market Perform 2026-09-23 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-18 29% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-10 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-08-06 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-06 62% win rate (8 calls)
Truist Securities - Reiterated
Buy → Buy 2026-07-14 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-09 Building track record
UBS - Reiterated
Buy → Buy 2026-05-07 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
20/30
Consensus clarity
20/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →